The score is held back primarily by weak financial performance (ongoing losses and 2025 margin pressure) despite a relatively conservative balance sheet and improved operating cash flow. Technical indicators also point to a bearish longer-term trend, and valuation is difficult to support due to negative earnings and no dividend yield data.
Positive Factors
Conservative balance sheet
Low leverage provides financial flexibility to fund multi-quarter product qualifications and absorb operational setbacks without immediate refinancing. A conservative capital structure supports sustained R&D and commercialization efforts, improving odds of reaching durable profitability over several quarters.
Improving operating cash flow
A shift to positive operating cash flow in 2024–2025 indicates improving cash generation from core operations. Sustained OCF reduces reliance on external financing for working capital and commercialization, strengthening the firm's ability to support customer scale-ups and continued product development.
Niche specialty additives business
The company targets specialty polymer additives and process tech, a niche with technical barriers and application-specific sales. Successful customer qualification can create recurring orders and sticky relationships, supporting long-term revenue durability and potential premium margins if adoption expands.
Negative Factors
Persistent net losses
Ongoing net losses have eroded equity and indicate core economics are not yet sustainable. Persistent losses constrain reinvestment, increase dependence on external capital, and risk shareholder dilution unless structural revenue growth or margin improvement is achieved over the medium term.
Gross profit deterioration
A negative gross profit in 2025 signals that unit-level economics deteriorated, likely from cost pressures or adverse product mix. This threatens margin sustainability and could prevent commercialization efforts from translating into durable profits unless pricing, mix or cost structure are corrected.
Weak and volatile free cash flow
Volatile, negative free cash flow limits the company's ability to self-fund commercialization, scale production, or weather setbacks. Continued weak FCF increases the likelihood of future equity or debt raises, which could dilute shareholders or pressure the conservative balance sheet during multi-year growth plans.
Nexam Chemical Holding AB (NEXAM) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr242.91M
Dividend YieldN/A
Average Volume (3M)55.96K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue Growth-1.89%
EPS Growth-59.17%
CountrySE
Employees53
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.05
Shares Outstanding102,493,350
10 Day Avg. Volume55,551
30 Day Avg. Volume55,962
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)1.18
Price to Sales (P/S)1.04
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nexam Chemical Holding AB Business Overview & Revenue Model
Company DescriptionNexam Chemical Holding AB (publ) develops solutions that enhance properties and performance of various polymers in Sweden, Europe and internationally. It provides various products that enhance the properties and durability of polyesters, polyethylene, polyamides, polyimides, and high temperature resins, as well as produces various functional chemicals, additive/functional masterbatches, and color masterbatches and compounds under the NEXAMITE and NEXIMID names; and polymer recycling and reactive recycling solutions. The company serves aerospace, electronics, pipes, and engineered foams industries. Nexam Chemical Holding AB (publ) was founded in 2009 and is headquartered in Lomma, Sweden.
How the Company Makes MoneyNexam Chemical generates revenue primarily through the sale of its specialty chemicals and polymer solutions to a diverse range of industries. The company's revenue model is centered around the development and commercialization of innovative chemical products that meet specific customer needs. Key revenue streams include direct sales of products, long-term supply agreements with major industry players, and collaborative partnerships for research and development projects. Nexam also benefits from strategic collaborations with other companies and research institutions, which can provide additional funding and resources for product development. Furthermore, the company may engage in licensing agreements for its proprietary technology, contributing to its overall earnings.
Nexam Chemical Holding AB Financial Statement Overview
Summary
Financials are mixed and below average: profitability remains weak with persistent net losses and a notable 2025 gross profit deterioration into negative territory. Positives include low leverage supporting flexibility and improving operating cash flow in 2024–2025, but free cash flow has been volatile/weak (negative in 2022–2024 and only flat in 2025).
Income Statement
28
Negative
Profitability remains weak: net losses persist across all reported years, and operating results are still negative. Revenue has been choppy and recently softened (2025 revenue down ~2.8% after growth in 2024). A major concern is the sharp deterioration in 2025 gross profit turning negative, despite positive EBITDA, which suggests cost pressure or unfavorable mix; the key positive is the improving trajectory versus 2023 (losses narrowed materially in 2024–2025).
Balance Sheet
66
Positive
The balance sheet looks relatively conservative with low leverage (debt-to-equity generally ~0.13–0.17), providing financial flexibility. However, ongoing net losses translate into consistently negative returns on equity and equity has trended down from 2021 to 2025, indicating gradual erosion of shareholder value if profitability does not improve.
Cash Flow
42
Neutral
Cash generation is mixed: operating cash flow improved to positive levels in 2024–2025 after negative periods (notably 2020–2023), which is a constructive trend. Offsetting this, free cash flow has been volatile and weak (negative in 2022–2024 and flat at 0 in 2025), indicating limited ability to fund growth and losses without relying on the balance sheet.
Breakdown
Dec 2025
Dec 2024
Dec 2023
Dec 2022
Dec 2021
Income Statement
Total Revenue
192.25M
199.58M
190.28M
221.76M
219.45M
Gross Profit
-11.81M
92.40M
81.79M
86.73M
84.48M
EBITDA
4.12M
10.52M
-5.01M
780.00K
6.30M
Net Income
-16.53M
-9.01M
-22.84M
-12.71M
-5.46M
Balance Sheet
Total Assets
225.95M
231.13M
245.81M
278.10M
284.35M
Cash, Cash Equivalents and Short-Term Investments
12.17M
2.88M
9.06M
22.88M
63.60M
Total Debt
28.22M
23.10M
26.15M
31.84M
27.72M
Total Liabilities
57.78M
47.82M
52.75M
62.48M
56.28M
Stockholders Equity
168.17M
183.31M
193.06M
215.62M
228.06M
Cash Flow
Free Cash Flow
0.00
-2.47M
-9.53M
-44.22M
516.00K
Operating Cash Flow
11.29M
7.43M
-352.00K
-11.10M
7.19M
Investing Cash Flow
-9.57M
-9.71M
-9.18M
-33.12M
-6.25M
Financing Cash Flow
1.44M
-3.06M
-5.17M
3.85M
33.23M
Nexam Chemical Holding AB Technical Analysis
Technical Analysis Sentiment
Negative
Last Price2.35
Price Trends
50DMA
2.78
Negative
100DMA
3.16
Negative
200DMA
3.44
Negative
Market Momentum
MACD
-0.12
Negative
RSI
42.60
Neutral
STOCH
43.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NEXAM, the sentiment is Negative. The current price of 2.35 is below the 20-day moving average (MA) of 2.39, below the 50-day MA of 2.78, and below the 200-day MA of 3.44, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 42.60 is Neutral, neither overbought nor oversold. The STOCH value of 43.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NEXAM.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 27, 2026